Related Experiment Video

Updated: May 12, 2026

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR (qPCR)
08:30

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR (qPCR)

Published on: May 16, 2012

microRNA-183 is an oncogene targeting Dkk-3 and SMAD4 in prostate cancer

K Ueno1, H Hirata, V Shahryari

  • 1Department of Urology, San Francisco Veterans Affairs Medical Center, University of California at San Francisco, 4150 Clement Street, San Francisco, CA 94121, USA.

British Journal of Cancer
|March 30, 2013
PubMed
Abstract

Insights

This study identified miR-183 as an oncogenic microRNA (miR) in prostate cancer (PC). Inhibition of miR-183 suppressed PC cell growth and tumor development, suggesting its potential as a biomarker and therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biomarker Discovery

Background:

  • Prostate cancer (PC) is a significant health concern.
  • Identifying oncogenic microRNAs (miRs) is crucial for understanding PC development.
  • Novel PC biomarkers and therapeutic targets are needed.

Purpose of the Study:

  • To identify oncogenic microRNAs (miRs) in prostate cancer (PC) using miR microarray.
  • To investigate the potential of identified miRs as PC biomarkers.
  • To explore the functional role of miR-183 in PC progression.

Main Methods:

  • Microarray and real-time PCR were used to analyze miR expression in PC cell lines and tissues.
  • Cell growth and wound-healing assays were performed using miR-183 knockdown inhibitors.
  • In vivo experiments in nude mice were conducted to assess tumor growth inhibition.

Main Results:

  • Three oncogenic miRs (miR-146a, miR-183, miR-767-5P) were identified.
  • miR-183 expression was significantly upregulated in PC cells and tissues, correlating with advanced disease and poorer survival.
  • miR-183 knockdown inhibited PC cell growth, motility, and tumor growth in vivo, with Dkk-3 and SMAD4 identified as target genes.

Conclusions:

  • Oncogenic miR-183 shows potential as a novel biomarker for prostate cancer (PC).
  • Inhibition of miR-183 may offer a therapeutic strategy for PC treatment.
  • Targeting miR-183 could be a promising approach for PC management.

More Related Videos

miRNA Expression Analyses in Prostate Cancer Clinical Tissues11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library08:40

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library

Published on: April 6, 2012

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic cells are...